EN DE
Watch HealthyWay Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

HealthyWay Inc (2587) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of HealthyWay Inc stock HK$1.65, price HK$0.64, upside +159.8%, quality 66 out of 100. Rating: strongly undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China

HI HealthyWay Inc logo Thin data Nov 12, 2026

HealthyWay Inc

2587 · HK

Cheap (62% below fair value) and solid company, but falling price: meets 2 of 3 rules.

Get notified free when this changes
Fair value HK$1.65 · Strongly undervalued 
Quality 66/100 
Healthy Growth (revenue 3y +40.0 %/yr in CNY) 
Low debt 
Generates free cash flow 
Ranks above peers (12/13) 
Last quarter vs. a year ago: revenue +50%, profit +30%. 
Thin margins · 3.2% net margin (TTM) 
Moderate moat 48/100 · thin data
Falling price (downtrend) 
Thin data 
Watch HealthyWay Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$60.00 HK$0.5800 Fair Value HK$1.65 Dec 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 12, 2026.

How to read this chart

22‑month range HK$0.5800 – HK$60.00 · fair‑value band HK$0.9500 – HK$2.06 · the HK$0.6350 price screens below the HK$1.65 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 12, 2026.

Follow HealthyWay in your weekly email

Every Wednesday you see whether HealthyWay is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

HealthyWay Inc., an investment holding company, provides corporate and digital marketing, and health and medical services in the People's Republic of China.

Show moreShow less

The company offers medical support services for individuals to manage their everyday health and wellness through health membership schemes and other medical support services, including medical consultation services, and supporting services to hospitals.

It also involved in the provision of healthcare service packages; and pharmaceutical sales business.

In addition, the company offers content services, including wellness content, precision content, and RWS support services; information technology services to corporate and institutional customers; and digital marketing services to advertisers through publishing and posting original marketing articles and brand-building advertisements through platform and other third-party online media channels.

Further, the company operates Yihu.com, a health and medical platform. HealthyWay Inc. was founded in 2001 and is headquartered in Fuzhou, the People's Republic of China.

Stock analysis

HealthyWay Inc (2587) currently trades at HK$0.6350, while our model-based Fair Value estimate is HK$1.65, implying the stock looks roughly 62% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of HK$3.35 per share, and 22 of the 24 models we run sit above the HK$0.6350 price.

Bear case: the Asset-Based group reads lowest at HK$0.2200, and 2 of the 24 models stay below the price. Data coverage for this calculation is low.

Scenario range: HK$0.9500 (bear) to HK$2.06 (bull), the price of HK$0.6350 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 66/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

HealthyWay Inc reported revenue of 1.6B CNY in FY2025 versus 431M CNY in FY2021, a compound +38.0%/yr. Reported net income was 55.7M CNY in FY2025.

Key figures

Market cap HK$557M (≈ $71.0M) Micro · P/E ratio 9.7 · P/S ratio 0.35 · Net margin 3.6% · Return on equity 22.1% · Return on assets (EBIT) −6.9% (5-year average) · Operating margin 1.2% · Revenue (TTM) 1.8B CNY.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).

What moves the price

The share trades about 90% below its 52-week high and 9% above its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 160%, 2587 screens cheaper than that median.

Fair Value models

Bear HK$0.9500 Fair Value HK$1.65 Bull HK$2.06
Price HK$0.6350 · Upside +159.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF HK$0.9900 HK$1.23 HK$1.91 77
Growth DCF HK$0.9500 HK$1.29 HK$1.81 76
Owner Earnings HK$0.7900 HK$1.18 HK$1.84 72
All 24 models by family
DCF Models
FCF DCF HK$0.9900 HK$1.23 HK$1.91 77
Owner Earnings HK$0.7900 HK$1.18 HK$1.84 72
5Y Revenue Exit HK$1.11 HK$1.66 HK$2.83 68
5Y EBITDA Exit HK$1.69 HK$2.84 HK$5.10 69
5Y P/E Exit HK$1.37 HK$2.66 HK$4.42 65
10Y Revenue Exit HK$1.03 HK$1.82 HK$2.32 64
10Y EBITDA Exit HK$1.41 HK$2.86 HK$5.43 62
10Y P/E Exit HK$1.22 HK$2.29 HK$4.06 58
Earnings-Based
Graham-Dodd HK$0.5100 HK$3.55 HK$4.98 60
Lynch FV HK$1.75 HK$2.50 HK$3.25 58
PEG = 1.0 HK$1.75 HK$2.50 HK$3.25 55
EPV HK$0.8100 HK$0.8600 HK$0.9000 71
Multiples
P/E Multiple HK$1.23 HK$1.65 HK$2.06 63
P/S Multiple HK$0.9500 HK$1.27 HK$1.59 58
P/B Multiple HK$0.9700 HK$1.30 HK$1.62 55
EV/EBIT HK$1.43 HK$1.78 HK$2.14 66
EV/EBITDA HK$2.11 HK$2.69 HK$3.28 67
EV/Revenue HK$1.12 HK$1.45 HK$1.77 54
Asset-Based
NCAV (Graham) HK$0.1400 HK$0.2200 HK$0.2700 54
Growth DCF
Growth DCF HK$0.9500 HK$1.29 HK$1.81 76
Rev-Margin DCF HK$1.18 HK$1.85 HK$3.23 67
Economic Profit
Residual Income HK$0.3700 HK$0.4900 HK$0.7500 66
ROIC Compounder HK$0.8200 HK$0.8800 HK$0.9300 69
Growth Earnings
Growth-Adj P/E HK$2.34 HK$3.35 HK$4.35 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 66/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 70
How much profit the company makes from its sales and capital
Quality Growth 90
Are margins and returns getting better?
Cashflow 35
Do the profits arrive as real cash?
Financial strength 70
Debt, balance sheet and risk of trouble
Investment 49
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 83
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 90/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+30.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+40.0%
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+0.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −1.2% a year for the price.

Watch 2587, get fair value alerts →

Compare HealthyWay Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 142 stocks

Beats the industry median on 11/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 66 · Top 25%
Fair Value upside +159.8% · Top 25%
Profitability
Return on equity (12 months) 22.1% · Top 25%
Return on assets 7.9% · Top 25%
Net margin (12 months) 3.2% · Above median
Operating margin (12 months) 1.2% · Below median
Growth and dividend
Revenue growth (quarter YoY) 49.7% · Top 25%

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/E (12 months) 9.7× · Cheapest 25%
P/B 1.71× · Cheaper than median
P/S (12 months) 0.26× · Cheapest 25%
Price / free cash flow (fiscal year) 11.8× · Cheaper than median
EV/EBITDA 2.7× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 16
FUTURE (revenue growth)100 · sector 43
PAST (return on equity)88 · sector 3
HEALTH (low debt)100 · sector 98
DIVIDEND (yield)0 · sector 44

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Veeva Systems Inc VEEV $301.53 $332.66 +10% vs 2587
Doximity, Inc DOCS $33.34 $36.67 +10% vs 2587
HealthEquity, Inc HQY $103.46 $113.36 +10% vs 2587
Waystar Holding WAY $27.99 $29.10 +4% vs 2587
Tempus AI, Inc TEM $71.60 $52.58 −27% vs 2587
HeartFlow, Inc HTFL $48.46 $30.56 −37% vs 2587
Hinge Health, Inc HNGE $115.39 $51.25 −56% vs 2587
Pro Medicus Limited PME A$201.66 A$85.12 −58% vs 2587
BrightSpring Health Services, Inc BTSG $71.21 $25.72 −64% vs 2587
XtalPi Holdings 2228 HK$5.87 HK$1.53 −74% vs 2587

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

HealthyWay Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "HealthyWay Inc Fair Value". https://www.fairvalue-calculator.com/stock/2587

Frequently asked questions

Is HealthyWay Inc (2587) overvalued or undervalued?
As of Nov 12, 2026, our model estimates a fair value of HK$1.65 versus a price of HK$0.6350, about +160% upside (undervalued).
What is the fair value of 2587?
Our model-based fair value for HealthyWay Inc is HK$1.65 (as of Nov 12, 2026), built from audited fundamentals. The current price: HK$0.6350.
What is the quality score of 2587?
HealthyWay Inc has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for HealthyWay Inc (2587)?
Our model-based price target is the fair value of HK$1.65 (as of Nov 12, 2026) from 24 valuation models. Cautious scenario HK$0.9500, optimistic scenario HK$2.06. It is a calculation from audited fundamentals, not an analyst target.
What is the HealthyWay Inc stock forecast for 2026?
Our models put fair value at HK$1.65, about +160% upside versus a price of HK$0.6350 (undervalued). Cautious scenario HK$0.9500, optimistic scenario HK$2.06. The calculation is refreshed regularly with new filings.
What is the revenue of HealthyWay Inc (2587)?
HealthyWay Inc reported trailing-twelve-month revenue of about 1.8B CNY (latest available figure, as of Nov 12, 2026).
What growth is priced into HealthyWay Inc (2587)?
For today's price to be fair in a discounted-cash-flow model, HealthyWay Inc would have to grow free cash flow by 0.4 % per year for five years (discount rate 13.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew 38.0 % per year. As of Nov 12, 2026.
What discount rate (WACC) does the fair value of 2587 use?
Our models discount HealthyWay Inc at 13.3 %: a base by market capitalisation (micro), country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For HealthyWay Inc that is +0.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.3 %) and the same formula as our fair value.
How much growth has HealthyWay Inc (2587) delivered so far?
Over the past 4 years revenue at HealthyWay Inc grew 38.0 % a year. The price currently implies free-cash-flow growth of +0.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of HealthyWay Inc (2587) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into HealthyWay Inc (+0.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of HealthyWay Inc (2587)?
The free-cash-flow yield on the price is 8.50 %: that much free cash flow HealthyWay Inc produces per unit of market value. When it exceeds the discount rate of our models (13.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of HealthyWay Inc (2587)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For HealthyWay Inc it is HK$1.65 per share (as of Nov 12, 2026), against a price of HK$0.6350. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is HealthyWay Inc stock overvalued or undervalued in 2026?
As of Nov 12, 2026, 2587 trades below its calculated fair value: price HK$0.6350, fair value HK$1.65, a gap of about +160% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2587?
No. The price is what the market pays today (HK$0.6350); the fair value is what the company's own numbers justify (HK$1.65). For HealthyWay Inc the two are HK$1.02 per share apart. That gap is exactly why we show both numbers side by side.
How much is HealthyWay Inc worth?
The market values HealthyWay Inc at about HK$557M (market capitalisation, as of Nov 12, 2026). Per share that is HK$0.6350; our models calculate a fair value of HK$1.65 per share.
What do the bullish and bearish scenarios say about 2587?
Our models span a range for HealthyWay Inc: cautious scenario HK$0.9500, base HK$1.65, optimistic HK$2.06 per share (as of Nov 12, 2026, price HK$0.6350). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 2587?
HealthyWay Inc trades at a price-to-earnings ratio of 9.7 (as of Nov 12, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$1.65 is built from several models across several years. Other multiples: P/B 1.7, P/S 0.3, EV/EBITDA 2.7.
How solid is the balance sheet of HealthyWay Inc (2587)?
Balance-sheet figures for HealthyWay Inc (as of Nov 12, 2026): return on equity 22.1%. They feed the Quality Score of 66/100, which measures business quality independently of the share price.
How far is 2587 from its 52-week high?
HealthyWay Inc trades at HK$0.6350, about 90% below its 52-week high of HK$6.26 and 9% above the low of HK$0.5800 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$1.65 is for.
Which stocks are comparable to HealthyWay Inc?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Tempus AI, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is HealthyWay Inc stock attractive at the current price?
The data as of Nov 12, 2026: price HK$0.6350, calculated fair value HK$1.65 (+160%), Quality Score 66/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2587 calculated?
We run HealthyWay Inc through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of HK$1.65 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. HealthyWay Inc currently trades 62% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of HealthyWay Inc (2587)?
The closing price on Nov 13, 2026 was HK$0.6350. Our model-based fair value is HK$1.65, about +160% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with HealthyWay Inc right now?
The price is below even our cautious bear case (HK$0.9500). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (66/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (HK$0.9500 to HK$2.06) leaves room in how you read the outcome.

Key figures of HealthyWay Inc

How large is the market capitalisation of HealthyWay Inc (2587)?
The market capitalisation of HealthyWay Inc is HK$557M (≈ $71.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of HealthyWay Inc (2587)?
The price-to-sales ratio of HealthyWay Inc is 0.35 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of HealthyWay Inc (2587)?
The net margin of HealthyWay Inc is 3.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of HealthyWay Inc (2587)?
The return on equity (ROE) of HealthyWay Inc is 22.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of HealthyWay Inc (2587)?
On an EBIT basis the return on assets of HealthyWay Inc is −6.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of HealthyWay Inc (2587)?
The operating margin of HealthyWay Inc is 1.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at HealthyWay Inc (2587)?
Revenue at HealthyWay Inc is growing 49.7% versus a year earlier (3y avg +40.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at HealthyWay Inc (2587)?
Earnings per share at HealthyWay Inc are growing 29.8% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed

Watch HealthyWay Inc in the live analysis

One click puts HealthyWay Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.